IMM - Immutep Limited
- Thread starter ozewolf
- Start date
- Joined
- 28 January 2008
- Posts
- 104
- Reactions
- 0
Who knows what the announcement will be, or what effect it will cause. All I know is that I really like the company and am holding for the long term.
If you feel so sure it will drop, then sell.
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
Today the announcement was made and the trading halt was lifted, the announcement was released, that a US company will be investing 25million dollars into PRR over a certin amount of time, there hasnt been a huge SP increase hovering around 12% up today, im still hanging on. waiting lol
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
WTF is going on with PRR? a supposedly good news release about a us investor, spiked up to 8c, then sliding down the next day to around 6.5c? what the hell is going on i cant work it out.
The pase 2 trials will take some considerable time.
If it passes the trial 2 phase with the FDA.
There is a further trail with the FDA phase 3 it will take years yet. If you look at the records of the FDA more products get knocked back than accepted.
It is a speculative stock.
If it does well you will make money.
Keep in mind they may change the stock at any time say reducing them say if you own 10,000 shares at present and bought at a cheap price they may combine at say 20 to 100 so you end up with 500 shares these small companies tend do that, once they have done this your parcel becomes worthless then they can buy back. I don't fully understand how or why this happens but they seem to get away with it. Therefore the investors that were there for the long haul get no dividends and nothing really for supporting the company through the hard times. Its the smart investors that make the money out of these stocks they don't care what the company is doing they are trading that's all. Take a look at IPL for example of what I have told you or eco on delisted.com
The news was simply that they had obtained finance to go into the next trial phase. The way the stock shot up to me represents danger I would have sold if I owned these stocks. These kind of stock shoot up if someone sneezes on hope.
However I could be very wrong I am wrong a lot of times please remember I am new to this.
If you look at the company announcements they are few and far between. The television interview is with one woman only on their web site.
I would have like to have seen a larger array of success stories. I personally now after learning the hard way to only trade in Blue chip stock they are dearer to buy but a much safer prospect with more transparency, you can make a lot more money trading in this kind of stock with much less risk. Make sure you do your research thoughly if you don't your just gambling.
What the hell are you on about? Are you saying that small-caps can just take your shares away? I really don't understand you. Are you taling about a reverse-split? Where 2 shares becomes 1 at double the price of the original?
Perhaps don't talk about something you seem to be making up.
Hey, blue chips are always safe. Look at BNB... And what do you mean they are "dearer" to buy?
- Joined
- 28 January 2008
- Posts
- 104
- Reactions
- 0
It is a speculative stock and it is currently in a growth period. In the US, the ovarian cancer market is worth about $2.1b, and headed for $3.6B in 2010. As far as the company is progressing in terms of trials and it's potential, for me it's worth having some dough in the company. I only have one speculative stock and this is it.
if a stock is re-rated your holding value is fixed, it's just the no. of shares you own changes in inverse proportion. So i don't know what you are talking about. But then again you said the said very same thing about yourself
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
I still can't work out PRR another trading halt yesterday they said it would be a halt till Friday, but today resumed trading, and dropped in share price after the following news release, i honestly don't know what to think of this company.
ASX/Media Release
Thursday 30 July 2009
PRIMA BIOMED SUBMITS CVAC™ IND APPLICATION WITH US FDA
• Investigational New Drug (IND) application major commercialisation milestone
for CVac™
Australian health care company Prima BioMed (Prima) (ASX: PRR) is pleased to
announce that is has submitted its Investigational New Drug (IND) application with the
US Food and Drug Administration (FDA) to evaluate the Company’s core product, the
CVac™ ovarian cancer therapy vaccine.
The submission of the IND with US FDA is one of the major milestones to be achieved
in the commercialisation process for CVac™, and represents one of the critical
requirements of the product’s development cycle. The granting of Investigational New
Drug status is a pre-requisite for all new drug human clinical trial required for FDA
approval for commercialisation.
The filing of the IND represents the culmination of years of scientific and pre-clinical
validation of the technology and commitment from Prima and its world class medical
advisory team. The IND submission is being managed by former US FDA Deputy
Director of Cell and Gene Therapy Dr. Joyce Frey-Vasconcells, currently Executive
Director, PharmaNet Consulting, and the Company looks forward to delivering the
outcomes of the IND to the market as soon they become available.
Prima BioMed Chairman said: “The submission of our IND application for CVac™ with
the US FDA is a major step forward in the development timeline for this product and
strengthens the potential for the CVac™ cancer vaccine immunotherapy to provide a
positive solution for ovarian cancer sufferers."
"We look forward to working closely with the FDA to continue to advance the
development of what we hope will be the first commercially available active cancer
vaccine immunotherapy product for women with ovarian cancer in the world,” Mr
Gokyildirim said.
The Company continues to make rapid progress towards commercialising CVac™
into the global multi-billion oncology pharmacy market. CVac™ is an ovarian cancer
therapy vaccine treatment which is administered post-surgery and post-chemotherapy
to delay relapse and control metastases. There is a large un-met medical need for
new treatments for ovarian cancer which has a very high morbidity rate, and at
present there are no maintenance-based therapy products commercially available.
ASX/Media Release
Thursday 30 July 2009
PRIMA BIOMED SUBMITS CVAC™ IND APPLICATION WITH US FDA
• Investigational New Drug (IND) application major commercialisation milestone
for CVac™
Australian health care company Prima BioMed (Prima) (ASX: PRR) is pleased to
announce that is has submitted its Investigational New Drug (IND) application with the
US Food and Drug Administration (FDA) to evaluate the Company’s core product, the
CVac™ ovarian cancer therapy vaccine.
The submission of the IND with US FDA is one of the major milestones to be achieved
in the commercialisation process for CVac™, and represents one of the critical
requirements of the product’s development cycle. The granting of Investigational New
Drug status is a pre-requisite for all new drug human clinical trial required for FDA
approval for commercialisation.
The filing of the IND represents the culmination of years of scientific and pre-clinical
validation of the technology and commitment from Prima and its world class medical
advisory team. The IND submission is being managed by former US FDA Deputy
Director of Cell and Gene Therapy Dr. Joyce Frey-Vasconcells, currently Executive
Director, PharmaNet Consulting, and the Company looks forward to delivering the
outcomes of the IND to the market as soon they become available.
Prima BioMed Chairman said: “The submission of our IND application for CVac™ with
the US FDA is a major step forward in the development timeline for this product and
strengthens the potential for the CVac™ cancer vaccine immunotherapy to provide a
positive solution for ovarian cancer sufferers."
"We look forward to working closely with the FDA to continue to advance the
development of what we hope will be the first commercially available active cancer
vaccine immunotherapy product for women with ovarian cancer in the world,” Mr
Gokyildirim said.
The Company continues to make rapid progress towards commercialising CVac™
into the global multi-billion oncology pharmacy market. CVac™ is an ovarian cancer
therapy vaccine treatment which is administered post-surgery and post-chemotherapy
to delay relapse and control metastases. There is a large un-met medical need for
new treatments for ovarian cancer which has a very high morbidity rate, and at
present there are no maintenance-based therapy products commercially available.
- Joined
- 28 January 2008
- Posts
- 104
- Reactions
- 0
You need to read more clearly:
-----------------------------------------------
.....The securities of Prima Biomed Limited (the “Company”) will be placed in pre-open at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in pre-open until the earlier of the commencement of normal trading on Friday, 31 July 2009 or when the announcement is released to the market.
Security Code: PRR
PRRO
-----------------------------------------------
-----------------------------------------------
.....The securities of Prima Biomed Limited (the “Company”) will be placed in pre-open at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in pre-open until the earlier of the commencement of normal trading on Friday, 31 July 2009 or when the announcement is released to the market.
Security Code: PRR
PRRO
-----------------------------------------------
ABN Amro 20th May 2009
Prima Biomed (PRR, Not formally covered)
We recently caught up with Martin Rogers Executive Director from Prima Biomed via a
teleconference. Prima Biomed has had a strong run recently (from A$0.03 to A$0.11)
following the successful results from a broadly similar company in the US Dendreon
(NASDAQ
NDN). DNDN released positive pivotal trial results for its treatment targeted at
prostate cancer.
Primas core compound CVac is a potential ovarian cancer therapy vaccine. Prima is setting
about divesting its non-core assets to focus on the CVac program. Its current cash reserves
of A$0.25m at 30 April are to be boosted by a placement to Laurence Freedman of A$1.5m, a
share purchase plan priced at A$0.07 and A$12m funding facility from Fortrend Securities.
Prima recently announced that it has commenced discussions with a potential North
American insitutional investment fund. The funds raised will enable a Phase IIb/III Pivotal trial
to be undertaken. Currently the company has commenced its Investigational New Drug
application for the FDA. It is anticipated that the trial could commence in September 2009.
The trial would take approximately two years to complete. Prima would explore partnering
opportunities during this time. An interesting play for investors with a high risk profile.
20% up today. Anyone with ideas why?
Prima Biomed (PRR, Not formally covered)
We recently caught up with Martin Rogers Executive Director from Prima Biomed via a
teleconference. Prima Biomed has had a strong run recently (from A$0.03 to A$0.11)
following the successful results from a broadly similar company in the US Dendreon
(NASDAQ
NDN). DNDN released positive pivotal trial results for its treatment targeted atprostate cancer.
Primas core compound CVac is a potential ovarian cancer therapy vaccine. Prima is setting
about divesting its non-core assets to focus on the CVac program. Its current cash reserves
of A$0.25m at 30 April are to be boosted by a placement to Laurence Freedman of A$1.5m, a
share purchase plan priced at A$0.07 and A$12m funding facility from Fortrend Securities.
Prima recently announced that it has commenced discussions with a potential North
American insitutional investment fund. The funds raised will enable a Phase IIb/III Pivotal trial
to be undertaken. Currently the company has commenced its Investigational New Drug
application for the FDA. It is anticipated that the trial could commence in September 2009.
The trial would take approximately two years to complete. Prima would explore partnering
opportunities during this time. An interesting play for investors with a high risk profile.
20% up today. Anyone with ideas why?
I know exactly why this happened on a business channel on austar the night before the stock shot up, a caller rang up to ask about the stock PRR the Broker was all over it, singing its praises. He has stock in the company, so low and behold the stock shot up. The other thing that came up during the show that evening was that the Broker sprouting PRR had had lunch with the CEO that very day, mmmmm. They were slapped with a speeding fine by the ASX and no one seems to know why the stock shot up MMMMMMMMMMMMM very fishy. This is defiantly a risky stock it is a long term hold years if they get FDA great if they don't you got nothing. 50 / 50 chance. I personally think the stock is way to expensive for the risk. They keep sprouting Dendon you must remember they are two separate companies with two separate products. I hope it works and you all make money however I personally see better investments in the market with less risk
This product was put under pressure by the last health Minster so they had to go back to the drawing board.
This product was put under pressure by the last health Minster so they had to go back to the drawing board.
Watched a replay of the business channel show on the weekend. Yes, you were right, the broker was all over the stock.
But, it still went up another 28% today.
How does that saying go "something about smoke and fire"
mmmm wonder what station or show it was on that yesterday,? don't get me wrong think it could be a great stock if they get approval. But stocks that spike for no reason is on either roomer or someone knows something we all don't. I stay away from stuff like that, I'm not really a day trader, if I was I would play the game.
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
After getting these on a sniff of success at .015c, i finally bailed today, at .10c, so im taking 6000.00 out of which 5k is profit, not sure if i did the right thing but i cant see this price staying up here for too long.
I think you can all go ahead "day trading" this stock for a while until the next big thing grabs everyone's attention. Volumes will TANK and there will be a lot of sad faces out there in a few months. Fair price for Prima right now is 0.045 - 0.052. I'm going to wait until then to get in.
But I also hope I'm wrong...what a lesson!
But I also hope I'm wrong...what a lesson!
I think you can all go ahead "day trading" this stock for a while until the next big thing grabs everyone's attention. Volumes will TANK and there will be a lot of sad faces out there in a few months. Fair price for Prima right now is 0.045 - 0.052. I'm going to wait until then to get in.
But I also hope I'm wrong...what a lesson!
Just wondering how you came up with a fair price of 0.045 - 0.052. I'm trying to learn how others value stocks. I have no idea what value I would give the company.
I don't hold any of the stock.
- Joined
- 17 May 2009
- Posts
- 3
- Reactions
- 0
Not sure where he valued it either but i own half million at 0.005 and having this much profit does nothing im holding on for dollars i guess about month hope!!!
Wish I had brought in last week before they had announced the next phase in their trials.
AAP
2009-08-31
Biotech Prima BioMed Ltd said on Monday that it had been advised by the United States Food and Drug Administration (FDA) that it could start its phase IIb clinical trial for its ovarian cancer vaccine treatment, CVac.
The phase IIb trial will be conducted using 60 patients at the Fred Hutchinson Cancer Centre in Seattle in the US.
The trial will seek to add to the positive efficacy results from Prima's previous phase IIa trial which was conducted in Australia.
Prima shares were 0.4 cents higher at 10 cents on Monday.
AAP
2009-08-31
Biotech Prima BioMed Ltd said on Monday that it had been advised by the United States Food and Drug Administration (FDA) that it could start its phase IIb clinical trial for its ovarian cancer vaccine treatment, CVac.
The phase IIb trial will be conducted using 60 patients at the Fred Hutchinson Cancer Centre in Seattle in the US.
The trial will seek to add to the positive efficacy results from Prima's previous phase IIa trial which was conducted in Australia.
Prima shares were 0.4 cents higher at 10 cents on Monday.
- Joined
- 28 January 2008
- Posts
- 104
- Reactions
- 0
Agreed totally.
I'm expecting a positive monotonic chart (moving average wise) for some time well into continuing trials. It's only a serious negative for the share price IF the trial ends up unfavorably which is ages away. Why people would even consider selling NOW is insane to me, but what do i know. It's a 10 share in the low market
- Joined
- 28 January 2008
- Posts
- 104
- Reactions
- 0
Out of interest for PRR's long term charting history, I include the 17 year weekly chart. There is 'long past' support/resistance line of approximately 25c (which st about 19c today, is currently about 20 to 30% from hitting it). At the rate PRR is rising the relevance of this line will possibly tested sooner than later.
